IMMIX BIOPHARMA INC.
1.6000
05-November-24 15:59:59
15 minutes delayed
Stocks
+0.0200
+1.27%
Today's range
1.4800 - 1.6000
ISIN
N/A
Source
NASDAQ
-
02 Oct 2024 09:32:00 By Nasdaq GlobeNewswire
-
Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
28 Aug 2024 09:32:00 By Nasdaq GlobeNewswire
-
25 Jul 2024 21:31:00 By Nasdaq GlobeNewswire
-
Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201
08 Jul 2024 09:31:00 By Nasdaq GlobeNewswire
-
Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum
17 Jun 2024 09:35:00 By Nasdaq GlobeNewswire
-
10 May 2024 09:35:00 By Nasdaq GlobeNewswire
-
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma
29 Apr 2024 09:39:00 By Nasdaq GlobeNewswire
-
Immix Biopharma on Track to Dose NXC-201 Patients in United States
18 Apr 2024 09:32:00 By Nasdaq GlobeNewswire
-
20 Mar 2024 09:46:00 By Nasdaq GlobeNewswire
-
Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative
05 Mar 2024 09:35:00 By Nasdaq GlobeNewswire
-
Immix Biopharma 12 Month Review Progress Update
21 Feb 2024 09:31:00 By Nasdaq GlobeNewswire
-
Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock
08 Feb 2024 16:45:00 By Nasdaq GlobeNewswire
-
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis
07 Feb 2024 09:37:00 By Nasdaq GlobeNewswire
-
Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock
05 Feb 2024 22:30:00 By Nasdaq GlobeNewswire
-
Immix Biopharma Announces Proposed Public Offering of Common Stock
05 Feb 2024 15:20:11 By Nasdaq GlobeNewswire
-
24 Jan 2024 08:35:00 By Nasdaq GlobeNewswire
-
18 Dec 2023 09:39:00 By Nasdaq GlobeNewswire
- <<
- <
- 1
- >